DNA NYSE Biological Products, (No Diagnostic Substances) Financials FY2019βFY2025
Ginkgo Bioworks Holdings, Inc. had $170M of revenue in fiscal 2025, down 25.1% on the year before. Over five years, revenue changed +17.3% a year on average.
Last close Β· Oct 23, 2026
$9.99
2.9%Hi! I read Ginkgo Bioworks Holdings, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β25.1%
No. Sales fell 25.1% last year.
Does it make a profit?
β183.8%
No. It lost money last year.
Does profit turn into cash?
β105.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Ginkgo Bioworks Holdings, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 5, 2026
Thursday Β· in 11 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 5, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 7, 2026 | Q1 '26 | After the market closes | 8-K β |
| Feb 26, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 6, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 7, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 6, 2025 | Q1 '25 | After the market closes | 8-K β |
| Feb 25, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 6, 2024 | Q3 '24 | Time not announced | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Ginkgo Bioworks Holdings, Inc. had $170M of revenue in fiscal 2025, down 25.1% on the year before. Over five years, revenue changed +17.3% a year on average. Its operating margin was β185.3%, up 61.3Β pts: of every 100 in sales, about β185 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Ginkgo Bioworks Holdings, Inc. lost $313M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$179M in fiscal 2025, β105.0% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Ginkgo Bioworks Holdings, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.6B | $1.3B | $944M | $562M | $423M |
| Interest coverage | β770.5x | β20,839.2x | β9,294.7x | β5,954.9x | β |
| Current ratio | 12.8x | 8.4x | 6.1x | 5.6x | 4.9x |
| Quick ratio | 12.8x | 8.4x | 6.1x | 5.6x | 4.9x |
| Total assets | $2.1B | $2.5B | $1.7B | $1.4B | $1.1B |
| Total liabilities | $504M | $803M | $568M | $661M | $611M |
| Shareholders' equity | $1.5B | $1.7B | $1.1B | $716M | $509M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Ginkgo Bioworks Holdings, Inc. passes 2 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 4 | 3 / 7 | 4 / 7 | 2 / 7 | 3 / 7 | 2 / 7 |
| Accruals ratio | β | 1.4% | β114.8% | β80.4% | β28.4% | β14.9% | β11.3% |
| Altman Z'' | β | 2.17 | β1.38 | β5.92 | β8.52 | β13.05 | β16.72 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $54.2M | $76.7M | $314M | $478M | $251M | $227M | $170M |
| Net interest income | β$48.2M | $12.2M | β$9.7M | β | β | β | β |
| Research and development | $96.3M | $160M | $1.1B | $1.1B | $581M | $424M | $244M |
| Operating income | β$71.6M | β$137M | β$1.8B | β$2.2B | β$864M | β$560M | β$315M |
| Interest expense | $2.4M | $2.4M | $2.4M | $0.1M | $0.1M | $0.1M | $0.0M |
| Pretax income | β$120M | β$125M | β$1.8B | β$2.1B | β$893M | β$548M | β$314M |
| Income tax | $0.0M | $1.9M | β$1.5M | β$15.0M | β$0.1M | β$0.5M | β$0.8M |
| Net income | β$119M | β$127M | β$1.8B | β$2.1B | β$893M | β$547M | β$313M |
| Diluted EPS | β$0.10 | β$0.10 | β$1.39 | β$50.20 | β$18.37 | β$10.54 | β$5.64 |
| Diluted shares | 1.15B | 1.27B | 1.36B | 0.04B | 0.05B | 0.05B | 0.06B |
| Cash flow | |||||||
| Cash from operations | β$44.7M | β$136M | β$254M | β$252M | β$296M | β$320M | β$171M |
| Capital expenditure | $22.2M | $57.8M | $56.5M | $52.3M | $40.8M | $62.5M | $7.7M |
| Free cash flow | β$66.9M | β$194M | β$310M | β$304M | β$336M | β$382M | β$179M |
| Depreciation and amortization | $10.8M | $13.9M | $29.1M | $42.6M | $70.5M | $63.0M | $59.0M |
| Stock-based compensation | $0.8M | $0.5M | $1.6B | $1.9B | $230M | $112M | $81.5M |
| Acquisitions | β | $0.0M | $12.0M | β$82.4M | $0.0M | $5.4M | $0.0M |
| Share buybacks | $0.4M | β | β | β | β | β | β |
| Dividends and buybacks | $0.4M | β | β | β | β | β | β |
| Balance sheet | |||||||
| Cash and short-term investments | $495M | $381M | $1.6B | $1.3B | $944M | $562M | $423M |
| Finance lease liabilities | β | β | β | $2.8M | $1.5M | β | $0.0M |
| Loans, net | β | β | β | $7.5M | $21.0M | $25.1M | $9.7M |
| Current assets | β | $427M | $1.7B | $1.5B | $1.0B | $603M | $472M |
| Current liabilities | β | $73.2M | $135M | $173M | $164M | $107M | $96.0M |
| Inventory | β | $2.7M | $3.4M | $4.4M | $0.0M | β | β |
| Property and equipment, net | β | $121M | $146M | $315M | $188M | $204M | $167M |
| Goodwill | $1.9M | $1.9M | $21.3M | $60.2M | $49.2M | $0.0M | β |
| Intangible assets | β | $3.3M | $21.6M | $111M | $82.7M | $72.5M | $53.5M |
| Total assets | β | $675M | $2.1B | $2.5B | $1.7B | $1.4B | $1.1B |
| Total liabilities | β | $205M | $504M | $803M | $568M | $661M | $611M |
| Preferred stock | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $502M | $461M | $1.5B | $1.7B | $1.1B | $716M | $509M |
| Margins | |||||||
| Operating margin | β132.1% | β178.8% | β582.6% | β462.4% | β343.8% | β246.5% | β185.3% |
| EBITDA margin | β112.3% | β160.7% | β573.4% | β453.5% | β315.7% | β218.8% | β150.6% |
| Net margin | β220.2% | β165.2% | β583.1% | β440.6% | β355.1% | β240.9% | β183.8% |
| FCF margin | β123.4% | β252.6% | β98.9% | β63.7% | β133.7% | β168.3% | β105.0% |
| Net interest share of revenue | β89.0% | 15.9% | β3.1% | β | β | β | β |
| Returns | |||||||
| Return on capital employed | β | β22.8% | β94.4% | β93.3% | β57.6% | β44.1% | β30.8% |
| Return on equity | β23.8% | β26.3% | β186.1% | β129.9% | β63.0% | β60.3% | β51.1% |
| Return on assets | β | β18.8% | β133.3% | β91.3% | β42.5% | β36.0% | β25.0% |
| Return on tangible equity | β23.9% | β27.8% | β125.1% | β134.5% | β92.5% | β85.0% | β68.7% |
| Growth | |||||||
| Revenue growth | β | 41.5% | 309.4% | 52.2% | β47.4% | β9.7% | β25.1% |
| Share count change | β | 10.9% | 6.7% | β96.9% | 15.8% | 6.8% | 6.9% |
| Financial health | |||||||
| Interest coverage | β29.6x | β57.5x | β770.5x | β20,839.2x | β9,294.7x | β5,954.9x | β |
| Current ratio | β | 5.8x | 12.8x | 8.4x | 6.1x | 5.6x | 4.9x |
| Quick ratio | β | 5.8x | 12.8x | 8.4x | 6.1x | 5.6x | 4.9x |
| Capital allocation | |||||||
| Capex / revenue | 41.0% | 75.4% | 18.0% | 10.9% | 16.2% | 27.5% | 4.5% |
| Stock comp / revenue | 1.4% | 0.6% | 511.7% | 404.1% | 91.4% | 49.5% | 47.9% |
| Quality scores | |||||||
| Piotroski F-score | β | β | 3.0 | 4.0 | 2.0 | 3.0 | 2.0 |
| Altman Z'' | β | 2.2 | β1.4 | β5.9 | β8.5 | β13.1 | β16.7 |
| Accruals ratio | β | 1.4% | β114.8% | β80.4% | β28.4% | β14.9% | β11.3% |
Source: SEC EDGAR XBRL filings (CIK 0001830214). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
